Navigation Links
Galderma Completes Acquisition of CollaGenex
Date:4/11/2008

LAUSANNE, Switzerland, April 11 /PRNewswire/ -- Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, today announced that its U.S. holding company, Galderma Laboratories, Inc., has completed its acquisition of CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI). As a result of the transaction, CollaGenex has become a wholly owned subsidiary of Galderma Laboratories.

"We are pleased to complete the acquisition process and are moving forward quickly to combine the two organizations to enable us to better serve dermatologists and the patients they serve," said Humberto C. Antunes, Chief Executive Officer of Galderma Pharma S.A. "CollaGenex's oral rosacea therapy will be an important complement to Galderma's topical products, and the two company's development pipelines have innovative compounds that have the potential to improve therapy and meet unmet needs."

CollaGenex's innovative products complement and enhance Galderma's portfolio for rosacea. Launched by CollaGenex in 2006 as the first FDA-approved systemic product, Oracea(R) is the only oral product indicated for the specific treatment of the inflammatory lesions of rosacea, and is a market leader in rosacea treatment products. Galderma's MetroGel(R) 1% is the leading topical drug for the treatment of inflammatory lesions of rosacea. Adding to this portfolio, Col-118 (brimonidine) is an innovative product under development for the treatment of erythema associated with rosacea.

Upon the closing of the acquisition, all remaining outstanding shares of CollaGenex common stock, other than those held by stockholders who properly perfect appraisal rights under Delaware law, were converted into the right to receive $16.60 per share in cash.

About Galderma

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company has a p
'/>"/>

SOURCE Galderma Pharma S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
2. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Carrington Completes $8 Million Financing
5. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
6. New Brunswick Scientific Completes Merger Transaction with Eppendorf
7. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
8. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
9. Optherion, Inc. Completes $37 Million Start Up Financing
10. Companys Partner Completes Trial Production of a New Antiviral Medicine
11. American Oriental Bioengineering Completes Acquisition of Guangxi Boke Pharmaceutical Company Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... "The interface is the device," Nobel laureate Herbert ... to be found at the junctures where layers ... of nanotechnology, the interfaces between layers of metal ... such high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics ...
(Date:1/15/2014)... Calif. (PRWEB) January 15, 2014 Cynvenio, ... and management through the genomic analysis of tumor cells ... Therapy Finder™, a web-based cancer decision support application powered ... option with Cynvenio’s ClearID™ genomic test, Therapy Finder will ...
(Date:1/15/2014)... More than 5 million Americans are currently ... seniors will die with Alzheimer’s or another dementia, according ... shocked many Americans into looking for ways to improve ... age-related cognitive disorders. Jonathan Weisman, president of Biohack Pure, ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... DuPont Senior,Vice President and Chief Science & Technology Officer ... in the formation of global,policy during a discussion at ... of science is to inform the policymaking process, to ... limits of what is,knowable, and what is possible," Chowdhry ...
... Massive Rebuilding Effort for Tornado-Torn ... Health Care Facility, ... struggle to rebuild following a devastating 2007 tornado,Siemens has announced that, ... Ga. facility with a new MAGNETOM ESSENZA, worth,approximately $800,000., Siemens ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today ... trial of a second generation oral niacin receptor agonist,under ... the,treatment of atherosclerosis and other disorders. The initiation of ... are very pleased with the progress of this collaboration,investigating ...
Cached Biology Technology:DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 3A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 3
(Date:4/18/2014)... of researchers led by a University of California, Riverside ... $7.5 million Department of Defense grant to uncover fundamental ... for the predictable design of light-weight, tough and strong ... from plants and animals, including the mantis shrimp, toucan ... have constructed over millions of years and coming up ...
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
(Date:4/17/2014)... Foundation has been named awardee of a three-year ... Defense Spinal Cord Injury Research Program. Gail Forrest, ... double-blinded, controlled, multi-site clinical trial, which will test ... spinal cord injury. Dr. Forrest is assistant director ... Foundation. Two additional sites will participate - the ...
Breaking Biology News(10 mins):Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
... El Nio was associated with higher mortality for eggs and ... could be worsened by continuing global climate change, according to ... PLoS ONE . The El Nio Southern Oscillation brought ... major nesting sites in the area. The researchers, led by ...
... 25, 2012 Babolat, international specialized tennis ... "Babolat Play & Connect," at the French Open. The ... nearly infinite potential. Welcome to the tennis of the ... first interactive racquet with organized demonstrations featuring amateur players ...
... in German . In the animal world, ... is the most beautiful. A well-known example is the peacock. The ... research team at Bielefeld University headed by the evolutionary biologist Dr. ... involved in mate choice among locusts. The male Siberian locust ( ...
Cached Biology News:"Babolat Play & Connect" - Worldwide Exclusive Event at the French Open 2"Babolat Play & Connect" - Worldwide Exclusive Event at the French Open 3"Babolat Play & Connect" - Worldwide Exclusive Event at the French Open 4A mating dance with Popeye arms 2
Request Info...
...
Collected from sexually mature mice....
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Biology Products: